| Year |
Citation |
Score |
| 2019 |
Decaup E, Rossi C, Gravelle P, Laurent C, Bordenave J, Tosolini M, Tourette A, Perrial E, Dumontet C, Poupot M, Klein C, Savina A, Fournié JJ, Bezombes C. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. Frontiers in Immunology. 10: 1943. PMID 31475004 DOI: 10.3389/Fimmu.2019.01943 |
0.357 |
|
| 2019 |
Guillon R, Rahimova R, Preeti, Egron D, Rouanet S, Dumontet C, Aghajari N, Jordheim LP, Chaloin L, Peyrottes S. Lead optimization and biological evaluation of fragment-based cN-II inhibitors. European Journal of Medicinal Chemistry. 168: 28-44. PMID 30798051 DOI: 10.1016/J.Ejmech.2019.02.040 |
0.317 |
|
| 2019 |
Alameh G, Emptoz-Bonneton A, Rolland de Ravel M, Matera EL, Mappus E, Balaguer P, Rocheblave L, Lomberget T, Dumontet C, Le Borgne M, Pugeat M, Grenot C, Cuilleron CY. In vitro modulation of multidrug resistance by pregnane steroids and in vivo inhibition of tumour development by 7α-OBz-11α(R)-OTHP-5β-pregnanedione in K562/R7 and H295R cell xenografts. Journal of Enzyme Inhibition and Medicinal Chemistry. 34: 684-691. PMID 30777494 DOI: 10.1080/14756366.2019.1575825 |
0.312 |
|
| 2019 |
Boyle EM, Davies FE, Deshpande S, Tytarenko RG, Ashby C, Wang Y, Wardell CP, Bauer MA, Johnson SK, Schinke CD, Thanendrarajan S, van Rhee F, Zangari M, Williams L, Facon T, ... Dumontet C, et al. Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma Blood. 134: 4333-4333. DOI: 10.1182/Blood-2019-126679 |
0.334 |
|
| 2018 |
Jordheim LP, Chettab K, Cros-Perrial E, Matera EL, Dumontet C. Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells. Pharmacology. 102: 161-168. PMID 30048976 DOI: 10.1159/000491587 |
0.336 |
|
| 2018 |
Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, ... ... Dumontet C, et al. Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma. Cancer Research. PMID 29559475 DOI: 10.1158/0008-5472.Can-17-1900 |
0.329 |
|
| 2018 |
Boyle EM, Rosenthal A, Wang Y, Farmer P, Rutherford MW, Ashby C, Bauer MA, Johnson SK, Wardell CP, Weinhold N, Hoering A, Dumontet C, Facon T, Schinke CD, Thanendrarajan S, et al. Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior Blood. 132: 4457-4457. DOI: 10.1182/Blood-2018-99-119113 |
0.346 |
|
| 2018 |
Boyle EM, Ashby C, Tytarenko RG, Wang Y, Bauer MA, Deshpande S, Johnson SK, Schinke CD, Thanendrarajan S, van Rhee F, Wardell C, Weinhold N, Facon T, Dumontet C, Morgan G, et al. Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria Blood. 132: 4456-4456. DOI: 10.1182/Blood-2018-99-117193 |
0.301 |
|
| 2018 |
Barret JM, Meseure D, Bataillon G, Andersson N, Auguste A, Dubreuil O, Färkkilä A, Perrial E, Bossard C, Loison E, Jarry A, Nicolas A, Lemée F, Gaillard S, Lahmar M, ... ... Dumontet C, et al. Abstract 774: Anti-Müllerian hormone type II receptor (AMHRII) found expressed in human non-gynecological solid tumors, suggesting potential broader applications for anti-AMHRII-based therapy Cancer Research. 78: 774-774. DOI: 10.1158/1538-7445.Am2018-774 |
0.306 |
|
| 2018 |
Cadassou O, Raza MZ, Cros-Perrial E, Armanet C, Gudefin L, Chettab K, Manié S, Dumontet C, Jordheim LP. Abstract 3164: Impact of cN-II and CD73 inhibition on cancer cell migration Tumor Biology. DOI: 10.1158/1538-7445.Am2018-3164 |
0.306 |
|
| 2017 |
Bricard G, Cadassou O, Cassagnes LE, Cros-Perrial E, Payen-Gay L, Puy JY, Lefebvre-Tournier I, Tozzi MG, Dumontet C, Jordheim LP. The cytosolic 5'-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells. Oncotarget. 8: 67380-67393. PMID 28978040 DOI: 10.18632/Oncotarget.18653 |
0.319 |
|
| 2017 |
Touzeau C, Moreau P, Dumontet C. Monoclonal antibody therapy in multiple myeloma. Leukemia. PMID 28210004 DOI: 10.1038/Leu.2017.60 |
0.317 |
|
| 2016 |
Rocheblave L, de Ravel MR, Monniot E, Tavenard J, Cuilleron CY, Grenot C, Radix S, Matera EL, Dumontet C, Walchshofer N. Deoxycholic acid derivatives as inhibitors of P-glycoprotein-mediated multidrug efflux. Steroids. 116: 5-12. PMID 27697501 DOI: 10.1016/J.Steroids.2016.09.017 |
0.322 |
|
| 2016 |
Sauveur J, Chettab A, matera E, Cleret A, Savina A, Dumontet C. Abstract 309: Mechanisms of resistance to trastuzumab emtansine in gastric cancer Cancer Research. 76: 309-309. DOI: 10.1158/1538-7445.Am2016-309 |
0.368 |
|
| 2015 |
Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzi?ski M, et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications. 6: 7539. PMID 26198393 DOI: 10.1038/Ncomms8539 |
0.319 |
|
| 2015 |
Cividini F, Cros-Perrial E, Pesi R, Machon C, Allegrini S, Camici M, Dumontet C, Jordheim LP, Tozzi MG. Cell proliferation and drug sensitivity of human glioblastoma cells are altered by the stable modulation of cytosolic 5′-nucleotidase II International Journal of Biochemistry and Cell Biology. 65: 222-229. PMID 26079827 DOI: 10.1016/J.Biocel.2015.06.011 |
0.358 |
|
| 2015 |
Jordheim LP, Puy JY, Cros-Perrial E, Peyrottes S, Lefebvre I, Périgaud C, Dumontet C. Determination of the enzymatic activity of cytosolic 5'-nucleotidase cN-II in cancer cells: development of a simple analytical method and related cell line models. Analytical and Bioanalytical Chemistry. PMID 25998135 DOI: 10.1007/S00216-015-8757-4 |
0.338 |
|
| 2015 |
Cividini F, Pesi R, Chaloin L, Allegrini S, Camici M, Cros-Perrial E, Dumontet C, Jordheim LP, Tozzi MG. The purine analog fludarabine acts as a cytosolic 5′-nucleotidase II inhibitor Biochemical Pharmacology. 94: 63-68. PMID 25656700 DOI: 10.1016/J.Bcp.2015.01.010 |
0.347 |
|
| 2015 |
Jordheim LP, Ribrag V, Ghesquieres H, Pallardy S, Delarue R, Tilly H, Haioun C, Jardin F, Demangel D, Salles GA, Dumontet C. Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma. Haematologica. 100: e204-6. PMID 25637052 DOI: 10.3324/Haematol.2014.120113 |
0.312 |
|
| 2015 |
Plesa A, Elhamri M, Clapisson G, Mattei E, Gazzo S, Hequet O, Tigaud I, Michallet M, Dumontet C, Thomas X. Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia. Leukemia & Lymphoma. 56: 622-9. PMID 24884314 DOI: 10.3109/10428194.2014.927453 |
0.344 |
|
| 2015 |
Hirz T, Esmenjaud J, Evesque A, Mathe-Poloni D, Dumontet C. Abstract 5014: Neutrophils protect B-cell lymphomas against chemotherapy via cell-cell interactions mediated by CD44 and ICAM1 receptors Immunology. 75: 5014-5014. DOI: 10.1158/1538-7445.Am2015-5014 |
0.334 |
|
| 2014 |
Jordheim LP, Cros-Perrial E, Matera EL, Bouledrak K, Dumontet C. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability. Clinical and Experimental Pharmacology & Physiology. 41: 817-24. PMID 25115435 DOI: 10.1111/1440-1681.12282 |
0.306 |
|
| 2014 |
Chaabane F, Krifa M, Matera E, Loussaeif A, Dijoux-Franca MG, Ghedira K, Dumontet C, Chekir-Ghedira L. In vitro antileukaemic activity of extracts from Daphne gnidium leaves against sensitive and multidrug resistant K562/R7 cells. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 35: 8991-8. PMID 24903378 DOI: 10.1007/S13277-014-2129-0 |
0.315 |
|
| 2014 |
Boespflug A, Thomas L, Rousset P, Dumontet C, Caramel J, Ferraro-Peyret C, Bringuier PP, Balme B, Dalle S. Abstract 5602: BRAF V600 mutated allelic specific imbalance (MASI) impact on sensitivity to vemurafenib Cancer Research. 74: 5602-5602. DOI: 10.1158/1538-7445.Am2014-5602 |
0.357 |
|
| 2014 |
Ziv E, Dean E, Hu D, Martino A, Serie D, Campa D, Aftab B, Bracci P, Buda G, Caswell J, Dumontet C, Dudziński M, Fejerman L, Greenberg A, Hunstman S, et al. Abstract 5078: Genome wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients Cancer Research. 74: 5078-5078. DOI: 10.1158/1538-7445.Am2014-5078 |
0.315 |
|
| 2014 |
Duong MN, Cleret A, Matera E, Chettab K, Poloni D, Valsesia-Wittmann S, Clémenceau B, Dumontet C. Abstract 3783: Adipocytes inhibit trastuzumab-mediated ADCC via induction of GDF15 Cancer Research. 74: 3783-3783. DOI: 10.1158/1538-7445.Am2014-3783 |
0.377 |
|
| 2014 |
Bossard C, Dumontet C, Jordheim LP. Abstract 3613: Opposite effects of adipocytes and adenosine on hematological cancer cell survival and proliferationin vitro Cancer Research. 74: 3613-3613. DOI: 10.1158/1538-7445.Am2014-3613 |
0.365 |
|
| 2013 |
Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S, Duong MN, Reslan L, Gerdes CA, Friess T, Baer U, ... ... Dumontet C, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Molecular Cancer Therapeutics. 12: 2031-42. PMID 23873847 DOI: 10.1158/1535-7163.Mct-12-1182 |
0.313 |
|
| 2013 |
Tagoug I, Jordheim LP, Herveau S, Matera EL, Huber AL, Chettab K, Manié S, Dumontet C. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3556-66. PMID 23674497 DOI: 10.1158/1078-0432.Ccr-12-3134 |
0.323 |
|
| 2013 |
Honorat M, Terreux R, Falson P, Di Pietro A, Dumontet C, Payen L. Localization of putative binding sites for cyclic guanosine monophosphate and the anti-cancer drug 5-fluoro-2'-deoxyuridine-5'-monophosphate on ABCC11 in silico models. Bmc Structural Biology. 13: 7. PMID 23641929 DOI: 10.1186/1472-6807-13-7 |
0.342 |
|
| 2013 |
Jordheim LP, Barakat KH, Heinrich-Balard L, Matera EL, Cros-Perrial E, Bouledrak K, El Sabeh R, Perez-Pineiro R, Wishart DS, Cohen R, Tuszynski J, Dumontet C. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. Molecular Pharmacology. 84: 12-24. PMID 23580445 DOI: 10.1124/Mol.112.082347 |
0.304 |
|
| 2013 |
Wetzel M, Nicolazzi C, Vallée F, Deckert J, Dumontet C, Plesa A, Kannt A, Mikol V, Chiron M, Vincent L, Blanc V. Abstract 4735: SAR650984: Characterization of a potent phase I humanized anti-CD38 antibody for the treatment of multiple myeloma and other hematologic malignancies. Cancer Research. 73: 4735-4735. DOI: 10.1158/1538-7445.Am2013-4735 |
0.33 |
|
| 2013 |
Osdal T, Jordheim LP, Popa M, Vikebø LM, Sulen A, Bedringaas SL, Sandvold ML, Booij B, Bruserud Ø, Gjertsen BT, Dumontet C, McCormack E. Abstract 3274: Combination of elacytarabine and daunorubicin is significantly more effective than combination of cytarabine and daunorubicin in primary patient xenografts of AML. Cancer Research. 73: 3274-3274. DOI: 10.1158/1538-7445.Am2013-3274 |
0.31 |
|
| 2012 |
Gonçalves A, Trédan O, Villanueva C, Dumontet C. [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)]. Bulletin Du Cancer. 99: 1183-91. PMID 23247898 DOI: 10.1684/Bdc.2012.1669 |
0.307 |
|
| 2012 |
Prudent R, Vassal-Stermann E, Nguyen CH, Pillet C, Martinez A, Prunier C, Barette C, Soleilhac E, Filhol O, Beghin A, Valdameri G, Honoré S, Aci-Sèche S, Grierson D, Antonipillai J, ... ... Dumontet C, et al. Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. Cancer Research. 72: 4429-39. PMID 22761334 DOI: 10.1158/0008-5472.Can-11-3342 |
0.323 |
|
| 2012 |
Michallet M, Sobh M, El-Cheikh J, Morisset S, Sirvent A, Reman O, Cornillon J, Tabrizi R, Milpied N, Harousseau J, Labussière-Wallet H, Nicolini FE, Dumontet C, Mohty M, Attal M, et al. Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs. Blood. 120: 3116-3116. DOI: 10.1182/Blood.V120.21.3116.3116 |
0.322 |
|
| 2012 |
Jordheim L, Ribrag V, Ghesquieres H, Pallardy S, Delarue R, Tilly H, Haioun C, Jardin F, Salles G, Dumontet C. Single Nucleotide Polymorphisms in ABCB1 and CBR1 Predict Toxicity to R-CHOP Type Regimens in Patients with Diffuse Non Hodgkin's Lymphoma Blood. 120: 1616-1616. DOI: 10.1182/Blood.V120.21.1616.1616 |
0.325 |
|
| 2012 |
Plesa A, Elhamri M, Clapisson G, Mattei E, Gazzo S, Hequet O, Michallet M, Dumontet C, Thomas X. Higher Percentage of CD34+CD38− Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predict Unsustained Complete Remission in AML Blood. 120: 1485-1485. DOI: 10.1182/Blood.V120.21.1485.1485 |
0.323 |
|
| 2012 |
Jordheim LP, Marton Z, Rhimi M, Chaloin L, Cros-Perrial E, Lionne C, Peyrottes S, Aghajari N, Dumontet C. Abstract 3835: Identification and characterization of inhibitors of 5′-nucleotidase cN-II issued from virtual screening Cancer Research. 72: 3835-3835. DOI: 10.1158/1538-7445.Am2012-3835 |
0.307 |
|
| 2011 |
Honorat M, Mesnier A, Vendrell J, Di Pietro A, Lin V, Dumontet C, Cohen P, Payen L. MRP8/ABCC11 expression is regulated by dexamethasone in breast cancer cells and is associated to progesterone receptor status in breast tumors. International Journal of Breast Cancer. 2011: 807380. PMID 22332017 DOI: 10.4061/2011/807380 |
0.309 |
|
| 2011 |
Thomas X, Chelghoum Y, Cannas G, Elhamri M, Labussière H, Tigaud I, Ducastelle S, Nicolini F, Dumontet C, Michallet M. Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making? Clinical Lymphoma, Myeloma & Leukemia. 11: 342-9. PMID 21816372 DOI: 10.1016/J.Clml.2011.06.003 |
0.334 |
|
| 2011 |
Tagoug I, Sauty De Chalon A, Dumontet C. Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. Plos One. 6: e22641. PMID 21799925 DOI: 10.1371/Journal.Pone.0022641 |
0.304 |
|
| 2011 |
Doléans-Jordheim A, Bergeron E, Bereyziat F, Ben-Larbi S, Dumitrescu O, Mazoyer MA, Morfin F, Dumontet C, Freney J, Jordheim LP. Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 30: 1249-56. PMID 21494911 DOI: 10.1007/S10096-011-1220-3 |
0.307 |
|
| 2011 |
Gougounon A, Abahssain H, Rigollet L, Elhamri M, Tigaud I, Chelghoum Y, Plesa A, Dumontet C, Michallet M, Thomas X. Minimally differentiated acute myeloid leukemia (FAB AML-M0): prognostic factors and treatment effects on survival--a retrospective study of 42 adult cases. Leukemia Research. 35: 1027-31. PMID 21397944 DOI: 10.1016/J.Leukres.2011.02.015 |
0.321 |
|
| 2011 |
Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, Friess T, Umana P, Klein C, Dumontet C. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Molecular Cancer Therapeutics. 10: 178-85. PMID 21220500 DOI: 10.1158/1535-7163.Mct-10-0385 |
0.308 |
|
| 2011 |
Jordheim LP, Sève P, Trédan O, Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. The Lancet. Oncology. 12: 693-702. PMID 21163702 DOI: 10.1016/S1470-2045(10)70244-8 |
0.331 |
|
| 2011 |
Jordheim LP, Plesa A, Dreano M, Cros-Perrial E, Keime C, Herveau S, Demangel D, Vendrell JA, Dumontet C. Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868. Cancer Chemotherapy and Pharmacology. 68: 97-105. PMID 20844879 DOI: 10.1007/S00280-010-1458-Y |
0.328 |
|
| 2010 |
Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. International Journal of Cancer. Journal International Du Cancer. 126: 545-62. PMID 19609946 DOI: 10.1002/Ijc.24750 |
0.37 |
|
| 2010 |
Tagoug I, Plesa A, Vendrell J, Dumontet C. Effect of Imids on Gene Expression Profiles of Fresh Human Myeloma Cells Blood. 116: 5013-5013. DOI: 10.1182/Blood.V116.21.5013.5013 |
0.373 |
|
| 2010 |
Tagoug I, Jordheim L, Huber A, Herveau S, Matera E, Manié S, Dumontet C. Insulin-Like Growth Factor 1 Potentiates the Cytotoxic Activity of Bortezomib Against Myeloma Cells Blood. 116: 3987-3987. DOI: 10.1182/Blood.V116.21.3987.3987 |
0.343 |
|
| 2010 |
Reslan L, Dalle S, Tournebize C, Herveau S, Cros E, Dumontet C. Comparison of Cytotoxic Mechanisms of Anti-CD20 Antibodies GA101 and Rituximab Against Fresh Chronic Lymphocytic Leukemia Cells Blood. 116: 2467-2467. DOI: 10.1182/Blood.V116.21.2467.2467 |
0.329 |
|
| 2010 |
Rouba H, Herveau S, Matera E, Laurier J, Dumontet C. 98: Reduced content of Tubulin binding cofactor C (TBCC) in breast cancer cells modifies progression into cell cycle and influences response to treatments Bulletin Du Cancer. 97: S79-S80. DOI: 10.1016/S0007-4551(15)31191-7 |
0.309 |
|
| 2009 |
Hébrard C, Cros-Perrial E, Clausen AR, Dumontet C, Piskur J, Jordheim LP. Bacterial deoxyribonucleoside kinases are poor suicide genes in mammalian cells. Nucleosides, Nucleotides & Nucleic Acids. 28: 1068-75. PMID 20183574 DOI: 10.1080/15257770903368393 |
0.32 |
|
| 2009 |
Beghin A, Belin S, Hage-Sleiman R, Hage Sleiman R, Brunet Manquat S, Goddard S, Tabone E, Jordheim LP, Treilleux I, Poupon MF, Diaz JJ, Dumontet C. ADP ribosylation factor like 2 (Arl2) regulates breast tumor aggressivity in immunodeficient mice. Plos One. 4: e7478. PMID 19829707 DOI: 10.1371/Journal.Pone.0007478 |
0.309 |
|
| 2009 |
Barakat KH, Torin Huzil J, Luchko T, Jordheim L, Dumontet C, Tuszynski J. Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach. Journal of Molecular Graphics & Modelling. 28: 113-30. PMID 19473860 DOI: 10.1016/J.Jmgm.2009.04.009 |
0.309 |
|
| 2009 |
Diab R, Jordheim LP, Degobert G, Peyrottes S, Périgaud C, Dumontet C, Fessi H. Preparation, characterization and in vitro evaluation of a new nucleotide analogue prodrug cyclodextrin inclusion complexes. Journal of Nanoscience and Nanotechnology. 9: 295-300. PMID 19441310 DOI: 10.1166/Jnn.2009.J075 |
0.311 |
|
| 2009 |
Dalle S, Dupire S, Brunet-Manquat S, Reslan L, Plesa A, Dumontet C. In vivo model of follicular lymphoma resistant to rituximab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 851-7. PMID 19188155 DOI: 10.1158/1078-0432.Ccr-08-1685 |
0.346 |
|
| 2009 |
Ghayad SE, Vendrell JA, Bieche I, Spyratos F, Dumontet C, Treilleux I, Lidereau R, Cohen PA. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. Journal of Molecular Endocrinology. 42: 87-103. PMID 18984771 DOI: 10.1677/Jme-08-0076 |
0.387 |
|
| 2009 |
Plesa A, Lesca G, Dhedin N, Sobh M, Michallet AS, Nicolini FE, Merle-Beral H, Garban F, Leblond V, Sagorny K, Morisset S, Calender A, Dumontet C, Leporrier M, Sutton L, et al. Expression of the Chemokine Receptor CXCR4, CXCL12G801A Gene polymorphism and SDF1 Plasma Levels in B-Cell Chronic Lymphocytic Leukemia (B-CLL): Correlation with PBSC Mobilisation, Disease Characteristics and Outcome. Blood. 114: 2336-2336. DOI: 10.1182/Blood.V114.22.2336.2336 |
0.362 |
|
| 2009 |
Jordheim LP, Degobert G, Diab R, Peyrottes S, Périgaud C, Dumontet C, Fessi H. Inclusion complexes of a nucleotide analogue with hydroxypropyl-beta- cyclodextrin Journal of Inclusion Phenomena and Macrocyclic Chemistry. 63: 11-16. DOI: 10.1007/S10847-008-9483-8 |
0.304 |
|
| 2008 |
Ghayad SE, Bieche I, Vendrell JA, Keime C, Lidereau R, Dumontet C, Cohen PA. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Science. 99: 1992-2003. PMID 19016759 DOI: 10.1016/S1359-6349(08)71494-0 |
0.386 |
|
| 2008 |
Béghin A, Matera EL, Brunet-Manquat S, Dumontet C. Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line Cell Cycle. 7: 3074-3082. PMID 18818514 DOI: 10.4161/Cc.7.19.6777 |
0.359 |
|
| 2008 |
Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di Leo A, Dumontet C. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4511-6. PMID 18628466 DOI: 10.1158/1078-0432.Ccr-07-4741 |
0.319 |
|
| 2008 |
Dalle S, Thieblemont C, Thomas L, Dumontet C. Monoclonal antibodies in clinical oncology Anti-Cancer Agents in Medicinal Chemistry. 8: 523-532. PMID 18537534 DOI: 10.2174/187152008784533071 |
0.316 |
|
| 2008 |
Honorat M, Mesnier A, Vendrell J, Guitton J, Bieche I, Lidereau R, Kruh GD, Dumontet C, Cohen P, Payen L. ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. Endocrine-Related Cancer. 15: 125-38. PMID 18310281 DOI: 10.1677/Erc-07-0189 |
0.341 |
|
| 2008 |
Sève P, Dumontet C. Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? The Lancet Oncology. 9: 168-175. PMID 18237851 DOI: 10.1016/S1470-2045(08)70029-9 |
0.343 |
|
| 2008 |
Plesa C, Le Q, Chelghoum Y, Elhamri M, Tigaud I, Anglaret B, Ducastelle S, Perrin M, Nicolini F, Belhabri A, Troncy J, Thiebaut A, Hayette S, Revesz D, Wattel E, ... Dumontet C, et al. Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience Clinical Leukemia. 2: 198-204. DOI: 10.3816/Clk.2008.N.025 |
0.314 |
|
| 2007 |
Sève P, Reiman T, Lai R, Hanson J, Santos C, Johnson L, Dabbagh L, Sawyer M, Dumontet C, Mackey JR. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemotherapy and Pharmacology. 60: 27-34. PMID 17021819 DOI: 10.1007/S00280-006-0343-1 |
0.301 |
|
| 2007 |
Dalle MS, Dumontet C. Rituximab: Mechanism of action and resistance Bulletin Du Cancer. 94: 198-202. DOI: 10.1684/Bdc.2007.0201 |
0.353 |
|
| 2007 |
Plesa A, Le Q, Revesz D, Thomas X, Ducastelle S, Nicolini FE, Michallet A, Mollet I, Dubois V, Clark M, Dumontet C, Raus N, Michallet M. Correlation between MRD and Chimerism Kinetics in CLL Patients after Myeloablative and Non-Myeloablative Allogeneic Hematopoïetic Stem Cell Transplantation. Blood. 110: 5048-5048. DOI: 10.1182/Blood.V110.11.5048.5048 |
0.315 |
|
| 2007 |
Plesa C, Le Q, Chelghoum Y, Elhamri M, Tigaud I, Anglaret B, Ducastelle S, Perrin M, Nicolini F, Belhabri A, Troncy J, Thiebaut A, Revesz D, Wattel E, Dumontet C, et al. Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience. Blood. 110: 4352-4352. DOI: 10.1182/Blood.V110.11.4352.4352 |
0.316 |
|
| 2006 |
Dumontet C, Thomas L, Bérard F, Gimonet JF, Coiffier B. A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma Bulletin Du Cancer. 93. PMID 17145574 DOI: 10.1684/Bdc.2006.0148 |
0.32 |
|
| 2006 |
Morschhauser F, Depil S, Jourdan E, Wetterwald M, Bouabdallah R, Marit G, Solal-Céligny P, Sebban C, Coiffier B, Chouaki N, Bauters F, Dumontet C. Phase II study of gemcitabine–dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma Annals of Oncology. 18: 370-375. PMID 17074972 DOI: 10.1093/Annonc/Mdl395 |
0.301 |
|
| 2006 |
Koubeissi A, Raad I, Ettouati L, Guilet D, Dumontet C, Paris J. Inhibition of P-glycoprotein-mediated multidrug efflux by aminomethylene and ketomethylene analogs of reversins Bioorganic and Medicinal Chemistry Letters. 16: 5700-5703. PMID 16950619 DOI: 10.1016/J.Bmcl.2006.07.059 |
0.301 |
|
| 2006 |
Moreau P, Voillat L, Benboubker L, Dumontet C, Mathiot C, Hulin C, Robillard N, Loiseau HA, Herault O, Garnache F, Varoqueaux N, Harousseau J, Bataille R. Rituximab in CD20 Positive Multiple Myeloma: A Prospective Study from the IFM Group. Blood. 108: 3577-3577. DOI: 10.1182/Blood.V108.11.3577.3577 |
0.353 |
|
| 2005 |
Sève P, Isaac S, Trédan O, Souquet P, Pachéco Y, Pérol M, Lafanéchère L, Penet A, Peiller E, Dumontet C. Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy Clinical Cancer Research. 11: 5481-5486. PMID 16061864 DOI: 10.1158/1078-0432.Ccr-05-0285 |
0.351 |
|
| 2005 |
Fernandez-Calotti P, Jordheim LP, Giordano M, Dumontet C, Galmarini CM. Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC) Leukemia and Lymphoma. 46: 335-346. PMID 15621823 DOI: 10.1080/10428190400015683 |
0.352 |
|
| 2004 |
Dumontet C, Jaffrezou JP, Tsuchiya E, Duran GE, Chen G, Derry WB, Wilson L, Jordan MA, Sikic BI. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Bulletin Du Cancer. 91: E81-112. PMID 15568225 |
0.698 |
|
| 2004 |
Thieblemont C, Bouafia F, Hornez E, Dumontet C, Tartas S, Antal D, Lemieux B, Traullé C, Espinouse D, Salles G, Coiffier B. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leukemia & Lymphoma. 45: 711-4. PMID 15160944 DOI: 10.1080/10428190310001615675 |
0.348 |
|
| 2004 |
Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR, Dumontet C. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. Bmc Pharmacology. 4: 8. PMID 15157282 DOI: 10.1186/1471-2210-4-8 |
0.367 |
|
| 2003 |
Jordheim L, Galmarini CM, Dumontet C. Drug resistance to cytotoxic nucleoside analogues Current Drug Targets. 4: 443-460. PMID 12866659 DOI: 10.2174/1389450033490957 |
0.323 |
|
| 2003 |
Thieblemont C, Dumontet C, Bouafia F, Hequet O, Arnaud P, Espinouse D, Felman P, Berger F, Salles G, Coiffier B. Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001. Leukemia & Lymphoma. 44: 257-62. PMID 12688342 DOI: 10.1080/1042819021000035680 |
0.308 |
|
| 2003 |
Dumontet C, Jaubert J, Sebban C, Bouafia F, Ardiet C, Tranchand B, Berger E, Lucas C, Guyotat D, Coiffier B. Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients Annals of Oncology. 14: 615-622. PMID 12649110 DOI: 10.1093/Annonc/Mdg158 |
0.314 |
|
| 2002 |
Thieblemont C, Chettab K, Felman P, Callet-Bauchu E, Traverse-Glehen A, Berger F, Dumontet C, Cerutti C, Baseggio L, Salles G, Paultre C, Coiffier B, McGregor J. Identification and validation of seven genes, as potential markers, for the differential diagnosis of small B cell lymphomas (small lymphocytic lymphoma, marginal zone B cell lymphoma and mantle cell lymphoma) by cDNA macroarrays analysis. Leukemia. 16: 2326-2329. PMID 12399979 DOI: 10.1038/Sj.Leu.2402691 |
0.311 |
|
| 2002 |
Thieblemont C, Felman P, Berger F, Dumontet C, Arnaud P, Hequet O, Arcache J, Callet-Bauchu E, Salles G, Coiffier B. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clinical Lymphoma. 3: 41-7. PMID 12141954 DOI: 10.3816/Clm.2002.N.010 |
0.337 |
|
| 2001 |
Galmarini CM, Graham K, Thomas X, Calvo F, Rousselot P, Jafaari AE, Cros E, Mackey JR, Dumontet C. Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia Blood. 98: 1922-1926. PMID 11535530 DOI: 10.1182/Blood.V98.6.1922 |
0.348 |
|
| 2001 |
Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, Leleu X, Hequet O, Salles G, Coiffier B. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. British Journal of Haematology. 113: 772-8. PMID 11380469 DOI: 10.1046/J.1365-2141.2001.02795.X |
0.339 |
|
| 2001 |
Dumontet C, Drai J, Thieblemont C, Hequet O, Espinouse D, Bouafia F, Salles G, Coiffier B. The superoxide dismutase content in erythrocytes predicts short-term toxicity of high-dose cyclophosphamide British Journal of Haematology. 112: 405-409. PMID 11167839 DOI: 10.1046/J.1365-2141.2001.02595.X |
0.331 |
|
| 2000 |
Dumontet C, Thieblemont C, Espinouse D, Bouafia F, Hequet O, Salles G, Coiffier B. A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors Leukemia. 14: 2159-2165. PMID 11187906 DOI: 10.1038/Sj.Leu.2401955 |
0.332 |
|
| 2000 |
Voog E, Bienvenu J, Warzocha K, Moullet I, Dumontet C, Thieblemont C, Monneret G, Gutowski M, Coiffier B, Salles G. Factors That Predict Chemotherapy-Induced Myelosuppression in Lymphoma Patients: Role of the Tumor Necrosis Factor Ligand-Receptor System Journal of Clinical Oncology. 18: 325-325. PMID 10637246 DOI: 10.1200/Jco.2000.18.2.325 |
0.307 |
|
| 1999 |
Dumontet C, Fabianowska-Majewska K, Mantincic D, Bauchu EC, Tigaud I, Gandhi V, Lepoivre M, Peters GJ, Rolland MO, Wyczechowska D, Fang X, Gazzo S, Voorn DA, Vanier-Viornery A, Mackey J. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. British Journal of Haematology. 106: 78-85. PMID 10444166 DOI: 10.1046/J.1365-2141.1999.01509.X |
0.328 |
|
| 1999 |
Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 1061-70. PMID 10071301 DOI: 10.1200/Jco.1999.17.3.1061 |
0.536 |
|
| 1998 |
Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard EM, Thieblemont C, Felman P, Coiffier B. Frequency and significance of anemia in non-Hodgkin's lymphoma patients Annals of Oncology. 9: 1109-1115. PMID 9834824 DOI: 10.1023/A:1008498705032 |
0.346 |
|
| 1998 |
Ketterer N, Salles G, Moullet I, Dumontet C, Eljaafari-Corbin A, Tremisi P, Thieblemont C, Durand B, Neidhardt-Berard E, Samaha H, Rigal D, Coiffier B. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies British Journal of Haematology. 103: 235-241. PMID 9792315 DOI: 10.1046/J.1365-2141.1998.00960.X |
0.368 |
|
| 1998 |
Samaha H, Dumontet C, Ketterer N, Moullet I, Thieblemont C, Bouafia F, Callet-Bauchu E, Felman P, Berger F, Salles G, Coiffier B. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia. 12: 1281-1287. PMID 9697885 DOI: 10.1038/Sj.Leu.2401121 |
0.337 |
|
| 1998 |
Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P, Dumontet C, Moullet I, Eljaafari-Corbin A, Neidhardt-Berard E, Bouafia F, Coiffier B. High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation Blood. 91: 3148-3155. DOI: 10.1182/Blood.V91.9.3148.3148_3148_3155 |
0.332 |
|
| 1997 |
Ketterer N, Salles G, Espinouse D, Dumontet C, Neidhardt-Berard EM, Moullet I, Bouafia F, Berger F, Felman P, Coiffier B. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma Annals of Oncology. 8: 701-704. PMID 9296227 DOI: 10.1023/A:1008278605751 |
0.35 |
|
| 1997 |
Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, Bryon PA, Coiffier B. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients Journal of Clinical Oncology. 15: 1587-1594. PMID 9193357 DOI: 10.1200/Jco.1997.15.4.1587 |
0.305 |
|
| 1997 |
Warzocha K, Salles G, Bienvenu J, Bastion Y, Dumontet C, Renard N, Neidhardt-Berard EM, Coiffier B. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. Journal of Clinical Oncology. 15: 499-508. PMID 9053471 DOI: 10.1200/Jco.1997.15.2.499 |
0.306 |
|
| 1997 |
Chen G, Durán GE, Steger KA, Lacayo NJ, Jaffrézou JP, Dumontet C, Sikic BI. Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. The Journal of Biological Chemistry. 272: 5974-82. PMID 9038218 DOI: 10.1074/Jbc.272.9.5974 |
0.697 |
|
| 1997 |
Tilly H, Gaulard P, Lepage E, Dumontet C, Diebold J, Plantier I, Berger F, Symann M, Petrella T, Lederlin P, Brière J. Primary Anaplastic Large-Cell Lymphoma in Adults: Clinical Presentation, Immunophenotype, and Outcome Blood. 90: 3727-3734. DOI: 10.1182/Blood.V90.9.3727 |
0.354 |
|
| 1996 |
Dumontet C, Durán GE, Steger KA, Murphy GL, Sussman HH, Sikic BI. Differential expression of tubulin isotypes during the cell cycle. Cell Motility and the Cytoskeleton. 35: 49-58. PMID 8874965 DOI: 10.1002/(Sici)1097-0169(1996)35:1<49::Aid-Cm4>3.0.Co;2-D |
0.541 |
|
| 1996 |
Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Research. 56: 1091-7. PMID 8640766 |
0.491 |
|
| 1995 |
Jaffrézou JP, Dumontet C, Derry WB, Durán G, Chen G, Tsuchiya E, Wilson L, Jordan MA, Sikic BI. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncology Research. 7: 517-27. PMID 8866664 |
0.531 |
|
| 1995 |
Beketic-Oreskovic L, Durán GE, Chen G, Dumontet C, Sikic BI. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. Journal of the National Cancer Institute. 87: 1593-602. PMID 7563202 DOI: 10.1093/Jnci/87.21.1593 |
0.57 |
|
| 1994 |
Geriniere L, Bastion Y, Dumontet C, Salles G, Espinouse D, Coiffier B. Heterogeneity of acute lymphoblastic leukemia in HIV-seropositive patients Annals of Oncology. 5: 437-440. PMID 7521205 DOI: 10.1093/Oxfordjournals.Annonc.A058876 |
0.304 |
|
| Show low-probability matches. |